High Risk Stage III Melanoma
1 clinical trials · Condition
◉ Watch High Risk Stage III Melanoma
| Record | Firm | Date |
|---|---|---|
| Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma (NCT00636168) | Bristol-Myers Squibb | 2008-06-30 |
Track High Risk Stage III Melanoma automatically
Every clearance here is in the API, with alerts when new ones post.